EvolutionaryScale, a biotech-focused AI research lab, has raised USD 142 million in a seed funding round led by Nat Friedman, Daniel Gross, and Lux Capital, with participation from Amazon and NVentures.
The company plans to use the funds to further expand the capabilities of its protein-generating AI models for scientific research.
EvolutionaryScale develops AI models for applications in the field of biotechnology. The company's core offering, ESM3, is a GenAI model trained on a dataset of 2.78 billion proteins, which can reason over the sequence, structure, and function of proteins, enabling it to generate novel proteins for use in drug discovery and materials science.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.